The goal of this study is to learn what happens to a single dose of enlicitide over time in a healthy participant's body when the participant is given a single dose of MK-7262 and what happens to a single dose of MK-7262 over time in a healthy participant's body when the participant is given a single dose of enlicitide.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
30
Oral administration
Oral administration
Celerion ( Site 0001)
Lincoln, Nebraska, United States
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of MK-7262
Blood samples will be collected at multiple time points to estimate the AUC0-inf of MK-7262.
Time frame: Predose and at designated time points post-dose (up to 8 days)
AUC0-inf of Enlicitide
Blood samples will be collected at multiple time points to estimate the AUC0-inf of enlicitide.
Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Maximum Plasma Concentration (Cmax) of MK-7262
Blood samples will be collected at multiple time points to estimate the steady-state Cmax of MK-7262.
Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Cmax of Enlicitide
Blood samples will be collected at multiple time points to estimate the steady-state Cmax of enlicitide.
Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Area Under the Concentration-Time Curve From Time 0 to 24 hours (AUC0-24) of MK-7262
Blood samples will be collected at multiple time points to estimate the AUC0-24 of MK-7262.
Time frame: Predose and at designated time points post-dose (up to 24 hours post-dose)
Area Under the Concentration-Time Curve From Time 0 to Last Quantifiable Sample (AUC0-last) of MK-7262
Blood samples will be collected at multiple time points to estimate the AUC0-last of MK-7262.
Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time to Maximum Plasma Concentration (Tmax) of MK-7262
Blood samples will be collected at multiple time points to estimate the Tmax of MK-7262.
Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Apparent Terminal Half-life (t1/2) of MK-7262
Blood samples will be collected at multiple time points to estimate the t1/2 of MK-7262.
Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Apparent Clearance (CL/F) of MK-7262
Blood samples will be collected at multiple time points to estimate the CL/F of MK-7262.
Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Apparent Volume of Distribution During Terminal Phase (Vz/F)of MK-7262
Blood samples will be collected at multiple time points to estimate the Vz/F of MK-7262.
Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)
AUC0-24 of Enlicitide
Blood samples will be collected at multiple time points to estimate the AUC0-24 of enlicitide.
Time frame: Predose and at designated time points post-dose (up to 24 hours post-dose)
AUC0-last of Enlicitide
Blood samples will be collected at multiple time points to estimate the AUC0-last of enlicitide.
Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Tmax of Enlicitide
Blood samples will be collected at multiple time points to estimate the Tmax of enlicitide.
Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)
t1/2 of Enlicitide
Blood samples will be collected at multiple time points to estimate the t1/2 of enlicitide.
Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)
CL/F of Enlicitide
Blood samples will be collected at multiple time points to estimate the CL/F of enlicitide.
Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Vz/F of Enlicitide
Blood samples will be collected at multiple time points to estimate the Vz/F of enlicitide.
Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Number of Participants Who Experience One or More Adverse Events (AEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants that experience AEs will be reported.
Time frame: Up to approximately 8 weeks
Number of Participants Who Discontinue Study Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants that discontinue study intervention due to an AE will be reported.
Time frame: Up to approximately 6 weeks